Breaking News Instant updates and real-time market news.

Ultragenyx plans to discontinue further clinical development of Ace-ER

16

Nov

RAREUltragenyx

$58.85

1.94 (3.41%)

08/16/17

EVER

08/16/17INITIATIONTarget $63EVERIn Line

Ultragenyx initiated with an In Line at Evercore ISI

Evercore ISI analyst Josh Schimmer initiated Ultragenyx with an In Line and a $63 price target.

07/27/17

07/27/17INITIATION

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kinder Morgan (KMI) initiated with a Neutral at Mizuho. 2. Alpine Immune Sciences (ALPN) initiated with a Buy at Ladenburg. 3. Synaptics (SYNA) resumed with an Outperform at Cowen. 4. BioMarin (BMRN) and Ultragenyx (RARE) were initiated with a Market Perform at Bernstein. 5. Keane Group (FRAC) and ProPetro Holding (PUMP) were initiated with an Overweight at Capital One. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

07/27/17

BERN

07/27/17INITIATIONBERNMarket Perform

Ultragenyx initiated with a Market Perform at Bernstein

Bernstein analyst Vincent Chen started coverage of Ultragenyx with a $72 price target and a Market Perform rating. The analyst views the stock as fully valued.

05/05/17

LEER

05/05/17NO CHANGETarget $89LEEROutperform

Ultragenyx price target lowered to $89 from $93 at Leerink

Leerink analyst Joseph Schwartz lowered his price target for Ultragenyx to $89 from $93 as he delays launch assumptions for triheptanoin programs to 2020 from 2019. Nonetheless, the analyst notes that the company announced pre-specified fracture healing data in X-linked hypophosphatemia patients who were enrolled in the recent Phase 3 study, which suggest burosumab is disease-modifying and correlates biomarker improvements to physiological benefit. He continues to assign 90% probability of success to burosumab, and reiterates an Outperform rating on the shares.

UP AFTER EARNINGS: Cintas (CTAS), up 2.9%... Micron (MU), up 2.8%. ALSO HIGHER: Editas Medicine (EDIT), up 3.1% after it received the EMA's orphan medicinal product designation for EDIT-101... Twitter (TWTR), up 1.8% after it said it will start testing longer, 280-character tweets with a small group. DOWN AFTER EARNINGS: Nike (NKE), down 3.2%. ALSO LOWER: Kornit Digital (KRNT), down 12.2% after it cut its third quarter revenue guidance... Westlake Chemical Partners (WLKP), down 8.3% after it filed to sell 4.5M units for limited partners... Intra-Cellular (ITCI), down 7.2% after it filed to sell $150M in common stock... Ascendis Pharma (ASND), down 4.3% after it announced an offering of $125M of ADSs.